Kantor T, Kantor A, Vu K, Meza-Wilson E
"Our findings highlight that, despite large increases in GLP-1 RA initiation, many patients stop these medications within a year, especially those without T2D, for whom insurance coverage may be limited, said Tricia Rodriguez, PhD, MPH, principal applied research scientist, Truveta and lead author of the study
Rybelsus is FDA-approved for type 2 diabetes and for reducing the risk of serious cardiovascular problems in people with type 2 diabetes
Withdrawal symptoms may include increased hunger, weight regain, unstable blood sugar levels, nausea, and changes in bowel habits
These facilities follow USP compounding standards and are subject to oversight from state and federal regulators
There was also a pronounced and dose-dependent effect on body weight gain